Literature DB >> 2570286

Effects of UK 69 578: a novel atriopeptidase inhibitor.

D B Northridge1, A G Jardine, C T Alabaster, P L Barclay, J M Connell, H J Dargie, S G Dilly, I N Findlay, A F Lever, G M Samuels.   

Abstract

UK 69 578 is a competitive inhibitor of endopeptidase 24.11 (the enzyme that degrades atrial natriuretic factor) in vitro. In vivo, UK 69 578 has renal and cardiovascular effects similar to low-dose atrial natriuretic factor infusion, and may be a useful agent in hypertension and heart failure.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2570286     DOI： 10.1016/s0140-6736(89)90714-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  29 in total

Review 1.  Heart failure in 10 years time: focus on pharmacological treatment.

Authors:  J J V McMurray
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 2.  The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides.

Authors:  A M Richards
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

3.  Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Authors:  Johanne A Windeløv; Nicolai J Wewer Albrechtsen; Rune E Kuhre; Sara L Jepsen; Daniel Hornburg; Jens Pedersen; Elisa P Jensen; Katrine D Galsgaard; Marie Winther-Sørensen; Anne Ørgaard; Carolyn F Deacon; Matthias Mann; Hannelouise Kissow; Bolette Hartmann; Jens J Holst
Journal:  Diabetologia       Date:  2017-07-01       Impact factor: 10.122

Review 4.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

5.  Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat.

Authors:  J E Kirk; M R Wilkins
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 6.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

7.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.

Authors:  S H Fettner; S Pai; G R Zhu; T Kosoglou; C R Banfield; V Batra
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Drug therapy in chronic heart failure.

Authors:  D B McKenzie; A J Cowley
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

9.  Effect of endopeptidase-24.11 inhibition and of atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat.

Authors:  J E Kirk; M R Wilkins
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 10.  Vasopeptidase inhibitors: will they have a role in clinical practice?

Authors:  Matthew I Worthley; Roberto Corti; Stephen G Worthley
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.